Stock 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-06-20 am EDT 		5-day change 1st Jan Change
18.72 HKD +0.86% Intraday chart for SciClone Pharmaceuticals (Holdings) Limited -.--% +34.48%
Jun. 26 SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director CI
Jun. 21 SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2021 2022 2023 2024
Capitalization 1 5,836 5,657 8,475 11,376
Enterprise Value (EV) 1 4,876 4,837 6,699 11,376
P/E ratio 6.5 x 6.85 x 8.09 x 10.6 x
Yield 3.29% 4.15% - 2.35%
Capitalization / Revenue 2.32 x 2.06 x 2.69 x 3.2 x
EV / Revenue 2.32 x 2.06 x 2.69 x 3.2 x
EV / EBITDA 5.21 x 4.66 x 6.23 x 8.26 x
EV / FCF 5,700,595 x 4,802,611 x - -
FCF Yield 0% 0% - -
Price to Book 2.43 x 1.92 x 2.77 x 2.91 x
Nbr of stocks (in thousands) 674,684 682,330 608,843 607,686
Reference price 2 8.650 8.290 13.92 18.72
Announcement Date 3/24/22 3/30/23 3/28/24 -
1HKD in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 1,919 2,518 2,750 3,156 3,556
EBITDA 1 - 1,121 1,213 1,361 1,378
EBIT 1 - 1,013 1,094 1,215 1,237
Operating Margin - 40.22% 39.78% 38.52% 34.79%
Earnings before Tax (EBT) 1 - 1,026 940.1 1,217 1,268
Net income 1 - 923.4 855.4 1,122 1,091
Net margin - 36.66% 31.11% 35.55% 30.68%
EPS 2 1.350 1.330 1.210 1.720 1.770
Free Cash Flow - 1,024 1,178 - -
FCF margin - 40.65% 42.83% - -
FCF Conversion (EBITDA) - 91.34% 97.12% - -
FCF Conversion (Net income) - 110.87% 137.7% - -
Dividend per Share 2 - 0.2849 0.3440 - 0.4400
Announcement Date 3/25/21 3/24/22 3/30/23 3/28/24 -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt - - - - -
Net Cash position - 960 819 1,776 -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - 1,024 1,178 - -
ROE (net income / shareholders' equity) - 70.2% 32.2% 35.9% 30.7%
ROA (Net income/ Total Assets) - 26.6% 20.4% 27% 25.3%
Assets 1 - 3,473 4,192 4,160 4,312
Book Value Per Share 2 - 3.560 4.310 5.020 6.440
Cash Flow per Share 2 - 1.480 1.670 2.160 1.710
Capex 1 - 5.7 5.77 77.6 185
Capex / Sales - 0.23% 0.21% 2.46% 5.2%
Announcement Date 3/25/21 3/24/22 3/30/23 3/28/24 -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED Stock SciClone Pharmaceuticals (Holdings) Limited
+34.48% 1.46B
CSL LIMITED Stock CSL Limited
+6.96% 101B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+8.29% 42.63B
BIOGEN INC. Stock Biogen Inc.
-11.09% 33.5B
UCB Stock UCB
+82.32% 29.77B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-11.82% 16.14B
INCYTE CORPORATION Stock Incyte Corporation
+1.39% 14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.13% 11.55B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+176.65% 10.53B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.74% 9.2B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 6600 Stock
  4. Financials SciClone Pharmaceuticals (Holdings) Limited